Prolonged Survival in Adult Patients with Neurofibromatosis Type I and Recurrent High Grade Gliomas Treated with Bevacizumab (P01.098)

Prolonged Survival in Adult Patients with Neurofibromatosis Type I and Recurrent High Grade Gliomas Treated with Bevacizumab (P01.098)

CONCLUSIONS: In this case series, adult patients with recurrent HGGs had prolonged overall and post-recurrence survival. These results suggest bevacizumab may be an effective therapy in NF1 patients with recurrent HGGs. Based on these observations, evaluation of bevacizumab responses in sporadic glioblastomas with NF1 mutations is warranted.Disclosure: Dr. Theeler has nothing to disclose. Dr. Ellezam has nothing to disclose. Dr. Slopis has nothing to disclose. Dr. Loghin has nothing to disclose. Dr. De Groot has received personal compensation for activities with Genentech, Inc., VBL Therapeutics, and Merck & Co., Inc. Dr. De Groot has received research support from Sanofi-Aventis Pharmaceuticals, Inc., AstraZeneca Pharmaceuticals, and EMD Serono. (Source: Neurology)

MedWorm Sponsor Message: Have a look at The Cancer and Oncology Daily, the new cancer portal with all the latest cancer news and research powered by MedWorm, updated daily.

View Source